HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies

Autor:	Kenneth H. Yu, Hayley Estrella, Teresa J. Melink, Paul W. Maffuid, David Kamins, Kirsten Dorr, Todd M. Bauer, John Gutheil, Judy Sing-Zan Wang, Eileen M. O'Reilly, Erkut Borazanci, Anna M. Varghese
Rok vydání:	2018
Předmět:	0301 basic medicine Cancer Research endocrine system diseases medicine.drug_class First line Monoclonal antibody Epitope 03 medical and health sciences chemistry.chemical_compound Pancreatic cancer 0502 economics and business medicine business.industry 05 social sciences Adhesion Sialyl-Lewis A medicine.disease digestive system diseases Gemcitabine 030104 developmental biology Oncology chemistry Cancer research 050211 marketing CA19-9 business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:e16235-e16235
ISSN:	1527-7755 0732-183X
Popis:	e16235Background: MVT-5873, a fully human IgG1 mAb, targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in PDAC and other GI and lung cancers, plays a role in tumor adhesion an...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::91cf0be4bd870814431b3b9ebb105252 https://doi.org/10.1200/jco.2018.36.15_suppl.e16235 Zobrazit plný text záznamu